Table 2. Results of the Receiver Operating Characteristic Curve Analyses.
| Characteristic | COVID-19 vs healthy controls | COVID-19 vs risk factor–matched controls | ||
|---|---|---|---|---|
| AUC (95% CI) | P value | AUC (95% CI) | P value | |
| Native T1 | 0.86 (0.80-0.92) | <.001 | 0.76 (0.69-0.83) | <.001 |
| Native T2 | 0.84 (0.78-0.91) | <.001 | 0.79 (0.73-0.85) | <.001 |
| LVEF | 0.70 (0.62-0.79) | <.001 | 0.62 (0.52-0.71) | .01 |
| LVEDV index | 0.65 (0.56-0.73) | .001 | 0.67 (0.58-0.75) | <.001 |
| LV mass index | 0.60 (0.49-0.70) | .07 | 0.63 (0.54-0.71) | <.001 |
| RVEF | 0.74 (0.66-0.83) | .001 | 0.61 (0.52-0.70) | .02 |
| hsTnT | 0.79 (0.72-0.86) | <.001 | 0.72 (0.57-0.76) | <.001 |
| NT-proBNP | 0.56 (0.46-0.65) | .21 | 0.52 (0.44-0.61) | .58 |
| High-sensitivity CRP | 0.54 (0.44-0.64) | .48 | 0.60 (0.52-0.76) | .05 |
Abbreviations: AUC, area under the receiver operating characteristic curve; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; hsTnT, high-sensitivity troponin T; LV, left ventricle; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro–b-type natriuretic peptide; RVEF, right ventricular ejection fraction.